Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharina Sahm

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Der Nervenarzt|January 3, 2024
[Immunotherapy against gliomas]Katharina Sahm, Tobias Weiss
Cancer Medicine|December 11, 2019
Autoimmune diseases and immunosuppressive therapy in relation to the risk of gliomaTareq M Anssar, Michael F Leitzmann, Ralf A Linker, et al.
Journal of Neuro-Oncology|January 13, 2026
Early distant progression in adult Histone-3 K27-altered diffuse midline gliomasNiklas Grassl, Abigail K Suwala, Tobias Kessler, et al.
Oncoimmunology|May 24, 2021
Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanomaXin-Wen Zhang, Katrin Huck, Kristine Jähne, et al.
Science Advances|February 2, 2024
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patientTamara Boschert, Kristina Kromer, Taga Lerner, et al.
Neuro-Oncology Advances|July 10, 2020
Molecular profiling-based decision for targeted therapies in <i>IDH</i> wild-type glioblastomaTobias Kessler, Anne Berberich, Belen Casalini, et al.
Communications Medicine|December 19, 2023
Concurrent gliomas in patients with multiple sclerosisKatharina Sahm, Tobias Kessler, Philipp Eisele, et al.
Theranostics|November 1, 2023
<i>In vivo</i> nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental gliomaJessica Hunger, Katharina Schregel, Berin Boztepe, et al.
Nature Communications|May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neurological Research and Practice|October 18, 2023
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasNiklas Grassl, Katharina Sahm, Heike Süße, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Der Nervenarzt|January 3, 2024
[Immunotherapy against gliomas]Katharina Sahm, Tobias Weiss
Cancer Medicine|December 11, 2019
Autoimmune diseases and immunosuppressive therapy in relation to the risk of gliomaTareq M Anssar, Michael F Leitzmann, Ralf A Linker, et al.
Journal of Neuro-Oncology|January 13, 2026
Early distant progression in adult Histone-3 K27-altered diffuse midline gliomasNiklas Grassl, Abigail K Suwala, Tobias Kessler, et al.
Oncoimmunology|May 24, 2021
Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanomaXin-Wen Zhang, Katrin Huck, Kristine Jähne, et al.
Science Advances|February 2, 2024
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patientTamara Boschert, Kristina Kromer, Taga Lerner, et al.
Neuro-Oncology Advances|July 10, 2020
Molecular profiling-based decision for targeted therapies in <i>IDH</i> wild-type glioblastomaTobias Kessler, Anne Berberich, Belen Casalini, et al.
Communications Medicine|December 19, 2023
Concurrent gliomas in patients with multiple sclerosisKatharina Sahm, Tobias Kessler, Philipp Eisele, et al.
Theranostics|November 1, 2023
<i>In vivo</i> nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental gliomaJessica Hunger, Katharina Schregel, Berin Boztepe, et al.
Nature Communications|May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trialFrank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neurological Research and Practice|October 18, 2023
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasNiklas Grassl, Katharina Sahm, Heike Süße, et al.
Pageof 2